PIKing the right patient

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• HER2 amplification and PIK3CA mutations are established biomarkers for phosphoinositide 3-kinase (PI3K) inhibitor sensitivity.
• Identifying broader patient populations responsive to PI3K inhibitors is crucial for effective breast cancer treatment.

Purpose of the Study:

• To validate known biomarkers for PI3K inhibitor GDC-0941.
• To develop a novel gene expression profile for identifying breast cancers sensitive to PI3K inhibitors.
• To explore pathway interactions and potential combination therapies.

Main Methods:

• Validation of HER2 amplification and PIK3CA mutation as predictive biomarkers.
• Development and application of a novel gene expression profiling method.
• Analysis of signaling network feedback loops involving TORC1, PI3K, and MAPK pathways.

Main Results:

• Confirmed HER2 amplification and PIK3CA mutation as predictive biomarkers for GDC-0941 sensitivity.
• Identified a novel expression profile capable of classifying additional breast cancers responsive to PI3K inhibition.
• Elucidated feedback mechanisms between TORC1, PI3K, and MAPK signaling pathways.

Conclusions:

• Biomarker-driven selection enhances PI3K inhibitor efficacy in breast cancer.
• Novel expression profiling expands the potential application of PI3K inhibitors.
• Understanding pathway crosstalk supports the development of rational combination therapies for improved clinical outcomes.